

## S 1803

### MEDS Act

**Congress:** 115 (2017–2019, Ended)

**Chamber:** Senate

**Policy Area:** Crime and Law Enforcement

**Introduced:** Sep 13, 2017

**Current Status:** Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure:

**Latest Action:** Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S5483-5484) (Sep 13, 2017)

**Official Text:** <https://www.congress.gov/bill/115th-congress/senate-bill/1803>

### Sponsor

**Name:** Sen. Hatch, Orrin G. [R-UT]

**Party:** Republican • **State:** UT • **Chamber:** Senate

### Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Coons, Christopher A. [D-DE]	D · DE		Sep 13, 2017
Sen. Gardner, Cory [R-CO]	R · CO		Sep 13, 2017
Sen. Schatz, Brian [D-HI]	D · HI		Sep 13, 2017
Sen. Tillis, Thomas [R-NC]	R · NC		Sep 13, 2017
Sen. Gillibrand, Kirsten E. [D-NY]	D · NY		Oct 2, 2017
Sen. Kaine, Tim [D-VA]	D · VA		Nov 13, 2017
Sen. Klobuchar, Amy [D-MN]	D · MN		Apr 25, 2018

### Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	Senate	Referred To	Sep 13, 2017

### Subjects & Policy Tags

#### Policy Area:

Crime and Law Enforcement

### Related Bills

Bill	Relationship	Last Action
115 HR 4825	Related bill	Jan 24, 2018: Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

## **Marijuana Effective Drug Studies Act of 2017 or the MEDS Act**

This bill amends the Controlled Substances Act to establish a new, separate registration process to facilitate research involving marijuana and the commercial production of drugs made from marijuana.

Specifically, the bill requires the Drug Enforcement Administration to register manufacturers and distributors to supply marijuana: (1) for use in research, and (2) for the commercial production of approved drugs containing or derived from marijuana.

### **Actions Timeline**

---

- **Sep 13, 2017:** Introduced in Senate
- **Sep 13, 2017:** Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S5483-5484)